Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAO report confirms appropriate FDA action on RU-486

Executive Summary

The Government Accountability Office confirms in an Aug. 7 report that FDA's approval and oversight of Danco Laboratories' Mifeprex (mifepristone), approved in 2000 for termination of early term pregnancy, was consistent with its regulatory approach to other Subpart H restricted drugs. Members of Congress had suggested that FDA approved Mifeprex (also known as RU-486) under Subpart H outside the regulation's original purpose (1"The Pink Sheet," April 30, 2007, p. 30). After reviewing the GAO report, Senate Health, Education, Labor and Pensions Committee Ranking Member Michael Enzi, R-Wyo., said, "While FDA's actions on RU-486 may have been consistent with the agency's actions on other drugs at the time, these actions were not sufficient to protect patient safety. ... This GAO report confirms that we did the right thing in [FDAAA]." Mifeprex is one of 16 drugs retroactively deemed to require Risk Evaluation & Mitigation Strategies, and Danco will have to adhere to the new requirements by September 21 (2"The Pink Sheet," March 31, 2008, p. 7)

You may also be interested in...



REMS Take Effect; FDA Identifies 16 Products With RiskMAPs That Qualify

Manufacturers of approved products whose marketing conditions qualify for a Risk Evaluation and Mitigation Strategy will have to develop a timeline for the assessment of their risk management efforts by September 21

Sen. Coburn Plays It Safe; FDA Will Review Medical Marijuana But Not RU-486

A path to federal legalization of state-sanctioned medical marijuana was approved by the Senate Health, Education, Labor and Pensions Committee as part of the markup of a bill renewing FDA's user fee program

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel